• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Neuroimmune Responses as a Beneficial Pathway on Remote Organ Damage from Acute Kidney Injury

Research Project

  • PDF
Project/Area Number 19K08721
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53040:Nephrology-related
Research InstitutionHamamatsu University School of Medicine

Principal Investigator

Yasuda Hideo  浜松医科大学, 医学部附属病院, 講師 (60432209)

Project Period (FY) 2019-04-01 – 2022-03-31
Keywords急性腎障害 / 急性肺障害 / マクロファージ / ニコチン性アセチルコリン受容体アゴニスト
Outline of Final Research Achievements

We hypothesized that activation of a nicotinic acetylcholine receptor (nAChR), which exerts cholinergic anti-inflammatory effects on macrophages, could reduce acute lung injury (ALI) after acute kidney injury (AKI). We induced AKI in male mice by unilateral ischemia-reperfusion injury (IRI) with contralateral nephrectomy and administered nAChR agonists in three experimental settings: 1) splenectomy, 2) deletion of splenic macrophages via intravenous administration of clodronate liposomes, and 3) alveolar macrophage deletion via intratracheal administration of clodronate liposomes. Treatment with GTS-21, an a7nAChR-selective agonist, significantly reduced the levels of circulating IL-6 and lung injury after renal IRI. The effect of GTS-21 on the lungs was eliminated in splenectomized mice and mice depleted of splenic macrophages, but not in mice with depleted alveolar macrophages. These findings suggest that nAChR agonist reduces ALI after IRI-induced AKI via macrophages in the spleen.

Free Research Field

急性腎障害

Academic Significance and Societal Importance of the Research Achievements

急性腎障害は高頻度、高死亡率な病態である。特に、透析を要する急性腎障害に多臓器障害を伴うと死亡率は40-50%程度と生命予後不良である。このように透析を行なっても急性腎障害の予後が悪いのは、急性腎障害からの臓器連関作用による多臓器障害によると考えられている。本研究では、ニコチン性アセチルコリン受容体アゴニストが脾臓マクロファージでの抗炎症経路を活性化して急性腎障害によって誘導される肺障害を軽減することを初めて明らかにした。本研究は、AKIによる臓器連関障害を軽減する新たな治療ストラテジーを提唱するもので、ニコチン性アセチルコリン受容体アゴニストの急性腎障害患者び対する臨床応用への礎となる。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi